Search
01/01/2024
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, C, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1)DOI:10.17650/1726-9776-2024-20-1-24-35. PMID:. IF:(Q/D).
01/01/2024
Oncological results of salvage treatment in patients with oropharynx carcinoma treated with radiotherapy
León X., Neumann E., Holgado A., Vásquez R., Pujol A., Quer M.. Oncological results of salvage treatment in patients with oropharynx carcinoma treated with radiotherapy. Acta Otorrinolaringologica Espanola. 2024; 75(1)DOI:10.1016/j.otorri.2023.01.002. PMID:. IF:(Q/D).
01/01/2024
Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period
Benjumea, C, Navarro, F, Tarrés, CA. Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period. JOURNAL OF MEDICAL MICROBIOLOGY. 2024; 73(6)DOI:10.1099/jmm.0.001846. PMID:38935081. IF:2.000(Q3/8D).
01/01/2024
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study
Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).
01/01/2024
Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry
Lugogo, NL, Heffler, E, Plaza, V, Hilberg, O, Xia, CM, Nash, S, Pandit, N, Jacob-Nara, JA, Sacks, HJ, Rowe, PJ, Deniz, Y, Hardin, M, Soler, X. Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry. Journal of Asthma and Allergy. 2024; 17DOI:10.2147/JAA.S451689. PMID:38860029. IF:3.000(Q2/4D).
01/01/2024
Chemsex Session Typologies and Associated Sociodemographic Factors in Sexual Minority Men: Latent Class Analysis From a Cultural Perspective Using a Cross-Sectional Survey
Gonzalez-Recio, P, Crossin, R, Donat, M, Palma, D, Caballero, DG, Moreno-Garcia, S, Guerras, JM, Belza, MJ. Chemsex Session Typologies and Associated Sociodemographic Factors in Sexual Minority Men: Latent Class Analysis From a Cultural Perspective Using a Cross-Sectional Survey. JMIR Public Health and Surveillance. 2024; 10DOI:10.2196/60012. PMID:39331536. IF:3.900(Q1/2D).